Drug Trial Radar · NCT03785249
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
731
Actual
Start
Jan 15, 2019
Primary completion
Jun 23, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Dec 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Conditions
- Advanced Cancer
- Metastatic Cancer
- Malignant Neoplastic Disease
Interventions
MRTX849Drug
MRTX849 will be administered orally once or twice daily in a continuous regimen
PembrolizumabDrug
Pembrolizumab is administered as an intravenous infusion once every 3 weeks
CetuximabDrug
Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks
AfatinibDrug
Afatinib will be administered orally once a day in a continuous regimen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Characterize the safety of MRTX849 in patients having advanced solid tumor malignancies with KRAS G12C mutationTime frame: 20 months
- Evaluate the pharmacokinetics of MRTX849Time frame: 20 months
- Evaluate clinical activity/efficacy of MRTX849Time frame: 20 months
Locations
222 sites in 2 countries. Site status is shown where the registry gives one.
Local Institution - 001-826
Birmingham, Alabama
Local Institution - 001-965
Anchorage, Alaska
Local Institution - 001-821
Phoenix, Arizona
Local Institution - 001-873-A
Tucson, Arizona
Local Institution - 001-873
Tucson, Arizona
Local Institution - 001-840-B
Bellflower, California
Local Institution - 001-834
Beverly Hills, California
Local Institution - 001-843
Duarte, California
Local Institution - 001-850-K
Dublin, California
Local Institution - 001-851
Fullerton, California
Local Institution - 001-840-C
Harbor City, California
Local Institution - 001-805
La Jolla, California
Local Institution - 001-779
Los Alamitos, California
Local Institution - 001-840
Los Angeles, California
Local Institution - 001-578
Los Angeles, California
Local Institution - 001-847
Newport Beach, California
Local Institution - 001-850-B
Oakland, California
Local Institution - 001-803
Orange, California
Local Institution - 001-850-C
Roseville, California
Local Institution - 001-850-J
Sacramento, California
Local Institution - 001-850-D
Sacramento, California
Local Institution - 001-845
San Diego, California
Local Institution - 001-840-A
San Diego, California
Local Institution - 001-850-H
San Francisco, California
Local Institution - 001-850-E
San Francisco, California
Local Institution - 001-850-F
San Jose, California
Local Institution - 001-850-A
San Leandro, California
Local Institution - 001-884
Santa Barbara, California
Local Institution - 001-850-I
Santa Clara, California
Local Institution - 001-884-A
Solvang, California
Local Institution - 001-850
Vallejo, California
Local Institution - 001-850-G
Walnut Creek, California
Local Institution - 001-872
Aurora, Colorado
Local Institution - 001-810
Aurora, Colorado
Local Institution - 001-872-H
Boulder, Colorado
Local Institution - 001-872-E
Colorado Springs, Colorado
Local Institution - 001-872-L
Colorado Springs, Colorado
Local Institution - 001-872-B
Denver, Colorado
Local Institution - 001-951 - A
Denver, Colorado
Local Institution - 001-951 - B
Denver, Colorado
Showing 40 of 222 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.